Shelton Capital Management’s Regenxbio RGNX Stock Holding History

Shelton Capital Management’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-2,935	Closed	-$222K	–	872
2018 Q3	$222K	Buy	+2,935	New	+$211K	0.01%	796

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

WS Management Jacksonville, Florida $1.14B AUM 139.27% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Shelton Capital Management's RGNX Position: Q4 2018 in Review

Shelton Capital Management sold out of Regenxbio (RGNX) in Q4 2018, closing a stake of 2,935 shares — an estimated $222K sold.

Shelton Capital Management first reported a position in RGNX in Q3 2018 and held it in 1 quarter. The position peaked at $222K in Q3 2018. 183 funds tracked by Wall St. Rank hold RGNX as of Q4 2018.

Shelton Capital Management reported no remaining Regenxbio position as of Q4 2018 after selling out during the quarter.
Shelton Capital Management sold 2,935 Regenxbio shares in Q4 2018, an estimated $222K.
Shelton Capital Management first reported a position in Regenxbio in Q3 2018 and held it in 1 quarter.
Shelton Capital Management's Regenxbio position peaked at $222K in Q3 2018.
183 funds tracked by Wall St. Rank held Regenxbio as of Q4 2018.

Based on Shelton Capital Management's 13F filing for Q4 2018, filed 31 Jan 2019.